M
Marina Pereira Collela
Researcher at State University of Campinas
Publications - 3
Citations - 63
Marina Pereira Collela is an academic researcher from State University of Campinas. The author has contributed to research in topics: Placebo & Antiphospholipid syndrome. The author has an hindex of 3, co-authored 3 publications receiving 45 citations.
Papers
More filters
Journal ArticleDOI
Recurrent thrombosis in antiphospholipid syndrome may be associated with cardiovascular risk factors and inflammatory response.
Sabrina da Silva Saraiva,Isadora Custódio,Bruna M Mazetto,Marina Pereira Collela,Erich Vinicius De Paula,Simone Appenzeller,Joyce Annichino-Bizzachi,Fernanda Andrade Orsi +7 more
TL;DR: The results suggest that arterial hypertension and monocyte counts may be independent factors for thrombosis recurrence in APS, and may support the evaluation of therapeutic measures to a rigid control of blood pressures and modulation of inflammatory response in APs, as additional prophylaxis against the recurrence of vascular events.
Journal ArticleDOI
Long-term increased factor VIII levels are associated to interleukin-6 levels but not to post-thrombotic syndrome in patients with deep venous thrombosis
Luis Fernando Bittar,Bruna M Mazetto,Fernanda Andrade Orsi,Marina Pereira Collela,Erich Vinicius De Paula,Joyce M. Annichino-Bizzacchi +5 more
TL;DR: It is demonstrated that DVT is associated with increased levels of inflammatory and coagulation markers, including FVIII, even a long time after the acute episode, and PTS seems to be related to inflammatory cytokine IL-8, a proinflammatory and proangiogenic chemokine, but not to FV III levels.
Journal ArticleDOI
SUSTAIN: A Multicenter, Randomized, Placebo-Controlled, Double-Blind, 12-Month Study to Assess Safety and Efficacy of SelG1 with or without Hydroxyurea Therapy in Sickle Cell Disease Patients with Sickle Cell-Related Pain Crises
Kenneth I. Ataga,Abdullah Kutlar,Julie Kanter,Darla K. Liles,Rodolfo D. Cançado,Joao Ricardo Friedrisch,Troy H. Guthrie,Jennifer Knight-Madden,Ofelia A. Alvarez,Victor R. Gordeuk,Sandra Fátima Menosi Gualandro,Marina Pereira Collela,Wally R. Smith,Scott A. Rollins,Jonathan W. Stocker,Russell P. Rother +15 more
TL;DR: The SUSTAIN study evaluated the safety of SelG1, a first-in-class humanized anti-P-selectin antibody, and its effect on the frequency of SCPC in SCD patients, a substantial cause of morbidity in sickle cell disease.